| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine DD Von Hoff, T Ervin, FP Arena, EG Chiorean, J Infante, M Moore, T Seay, ... New England Journal of Medicine 369 (18), 1691-1703, 2013 | 6614 | 2013 |
| Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial DD Von Hoff, RK Ramanathan, MJ Borad, DA Laheru, LS Smith, TE Wood, ... Journal of Clinical Oncology 29 (34), 4548, 2011 | 1229 | 2011 |
| Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung … MA Socinski, I Bondarenko, NA Karaseva, AM Makhson, I Vynnychenko, ... J Clin Oncol 30 (17), 2055-2062, 2012 | 871 | 2012 |
| Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non–small-cell lung cancer: a phase II study JJ Rusthoven, E Eisenhauer, C Butts, R Gregg, J Dancey, B Fisher, ... Journal of clinical oncology 17 (4), 1194-1194, 1999 | 322 | 1999 |
| Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial M Blackstein, CL Vogel, R Ambinder, J Cowan, J Iglesias, A Melemed Oncology 62 (1), 2-8, 2002 | 230 | 2002 |
| Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma: a phase II study by the National Cancer … M Crump, T Baetz, S Couban, A Belch, D Marcellus, K Howson‐Jan, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 205 | 2004 |
| Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer … T Baetz, A Belch, S Couban, K Imrie, J Yau, R Myers, K Ding, N Paul, ... Annals of Oncology 14 (12), 1762-1767, 2003 | 188 | 2003 |
| Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas … DD Von Hoff, TJ Ervin, FP Arena, EG Chiorean, JR Infante, MJ Moore, ... Journal of Clinical Oncology 31 (4_suppl), LBA148-LBA148, 2013 | 183 | 2013 |
| Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival WJ Gradishar, D Krasnojon, S Cheporov, AN Makhson, GM Manikhas, ... Clinical breast cancer 12 (5), 313-321, 2012 | 146 | 2012 |
| Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. FA Shepherd, RP Abratt, H Anderson, U Gatzemeier, G Anglin, J Iglesias Seminars in oncology 24 (2 Suppl 7), S7-50, 1997 | 131 | 1997 |
| A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer MA Socinski, GM Manikhas, DL Stroyakovsky, AN Makhson, SV Cheporov, ... Journal of Thoracic Oncology 5 (6), 852-861, 2010 | 114 | 2010 |
| Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study C Cripps, M Burnell, J Jolivet, G Batist, W Lofters, J Dancey, J Iglesias, ... Annals of oncology 10 (10), 1175-1179, 1999 | 110 | 1999 |
| SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study DD Von Hoff, R Ramanathan, M Borad, D Laheru, L Smith, T Wood, ... Journal of Clinical Oncology 27 (15_suppl), 4525-4525, 2009 | 108 | 2009 |
| Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer K Gelmon, E Eisenhauer, C Bryce, A Tolcher, L Mayer, E Tomlinson, ... Journal of clinical oncology 17 (10), 3038-3047, 1999 | 106 | 1999 |
| Phase II study of gemcitabine in patients with metastatic breast cancer M Blackstein, CL Vogel, R Ambinder, J Cowan, P Pearce, J Iglesias European Journal of Cancer 33 (S8), S149-S149, 1997 | 88 | 1997 |
| Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of … DD Von Hoff, TJ Ervin, FP Arena, EG Chiorean, JR Infante, MJ Moore, ... Journal of Clinical Oncology 31 (15_suppl), 4005-4005, 2013 | 57 | 2013 |
| nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis J O’Shaughnessy, WJ Gradishar, P Bhar, J Iglesias Breast cancer research and treatment 138, 829-837, 2013 | 55 | 2013 |
| The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer FA Shepherd, R Abratt, L Crino, M Green, A Sandler, W Steward, ... Lung Cancer 30 (2), 117-125, 2000 | 55 | 2000 |
| A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer SJ Clarke, MJ Boyer, M Millward, C Underhill, E Moylan, D Yip, S White, ... Lung Cancer 49 (3), 401-412, 2005 | 41 | 2005 |
| A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma S Pal, A Azad, S Bhatia, H Drabkin, B Costello, J Sarantopoulos, ... Clinical Cancer Research 21 (15), 3420-3427, 2015 | 35 | 2015 |
